-
1 Comment
Tibet Weixinkang Medicine Co., Ltd is currently in a long term downtrend where the price is trading 10.4% below its 200 day moving average.
From a valuation standpoint, the stock is 49.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.9.
Tibet Weixinkang Medicine Co., Ltd's total revenue sank by 8.1% to $185M since the same quarter in the previous year.
Its net income has increased by 130.2% to $16M since the same quarter in the previous year.
Finally, its free cash flow grew by 412.8% to $36M since the same quarter in the previous year.
Based on the above factors, Tibet Weixinkang Medicine Co., Ltd gets an overall score of 3/5.
Industry | Drug Manufacturers - Specialty & Generic |
---|---|
Sector | Healthcare |
Exchange | SHG |
CurrencyCode | CNY |
ISIN | CNE100002QQ3 |
Beta | 0.04 |
---|---|
Market Cap | 4B |
PE Ratio | 18.64 |
Target Price | None |
Dividend Yield | None |
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases, and other special fields. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is based in Lhasa, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603676.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025